Drug Type Antibody |
Synonyms SL 425, SL425 |
Target |
Mechanism DR3 modulators(Tumor necrosis factor receptor superfamily member 25 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Bowel Diseases | Preclinical | US | 11 Oct 2024 |